Navigation Links
NxStage Announces New FREEDOM Data Showing the Positive Impact of its Daily Home Hemodialysis Therapy on Sleep Quality and Restless Legs Syndrome
Date:3/8/2010

LAWRENCE, Mass. and SEATTLE, March 8 /PRNewswire-FirstCall/ -- Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study, which show the significant improvement of overall sleep quality and marked improvement in Restless Legs Syndrome (RLS) experienced by patients after four months of daily home hemodialysis therapy with the NxStage System One™.

These interim results from the FREEDOM study compared patients' responses to the Medical Outcomes Study (MOS) Sleep Survey and the International RLS Study Group Rating Scale (IRLS) at baseline and four months. Specifically, significant improvements identified in this planned interim analysis included:

  • Overall sleep quality (as measure by the MOS Sleep Problems Indices I and II) significantly improved from baseline to month four. (Index I: P=<0.001; Index II: P<0.0001)

  • Four of the 5 individual sleep scale s– sleep adequacy, daytime somnolence (or "drowsiness"), sleep initiation and maintenance, and respiratory disturbances – displayed significant improvement.

  • There was a significant reduction in the number of patients reporting RLS at 4 months compared to baseline. (P=0.02)

  • Of those patients who experienced RLS at baseline (n=58), 36% no longer experienced RLS at month four.

Dr. Brigitte Schiller, MD, Acting Chief Medical Officer and Vice President of Scientific Affairs for Satellite Healthcare headquartered in Mountain View, CA, is one of the presenters of FREEDOM study data during the 30th Annual Dialysis Conference in Seattle.

"Various studies suggest a high prevalence of sleep-related disorders and RLS, among End-stage Renal Disease (ESRD) patients. These interim results from the ongoing FREEDOM study demonstrate the positive impact of daily home hemodialysis on these disorders, which can have a significant impact on patients' quality of life," says Dr. Schiller. "Quality sleep is essential, and to ESRD patients in particular, as it has been proven to affect other areas of patients' overall health. Although these findings are only at four months, longer-term follow up is underway to determine whether the positive impact of daily home dialysis on sleep patterns and RLS persists at one year."

"NxStage continues to invest in proving the wide range of clinical and quality of life benefits possible with more frequent hemodialysis," says Jeff Burbank, CEO of NxStage Medical, Inc. "These results add to the growing evidence supporting daily home hemodialysis with our System One versus conventional, thrice-weekly in-center therapy."

The ongoing FREEDOM study is the largest study of its kind to measure the clinical and economic benefits of daily home hemodialysis treatment, as compared to conventional, thrice-weekly in-center hemodialysis treatment for patients requiring dialysis therapy. All daily home hemodialysis patients in the FREEDOM study use the NxStage System One as their treatment delivery system, and all have Medicare as their primary insurance payer.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    
    
    Kristen K. Sheppard, Esq.
    VP, Investor Relations
    ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.

Back to top

RELATED LINKS
http://www.nxstage.com

'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Medical Completes Acquisition of Medisystems
2. NxStage Medical Reports Third Quarter 2007 Results
3. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
4. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
5. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
6. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
7. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
8. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
9. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
10. NxStage Medical Reports First Quarter 2008 Results
11. NxStage Announces $43 Million Private Placement of Equity Securities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to ... the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of ... Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ dental ... in media for its creos™ line of bone regenerative products. Specifically, the ... which he utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... ... biographical account following a man who went on to support his country and serve the ... Lynn Haven, Florida and at the age of 5, his family moved to Pensacola Florida. ... Navy and got married right out of boot camp. , He and his wife ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017  Ethicon Endo-Surgery, Inc. announced today ... Inc., a privately held medical device company ... used in operating rooms worldwide. The acquisition ... energy devices with Megadyne,s innovative portfolio of ... in Ethicon,s goal to deliver the most ...
(Date:1/20/2017)... -- Wells Specialty Pharmacy announces the acquisitions and merger of ... Winter Park, Florida and Pharm-EZ Medical, LLC, ... been consolidated into the 3796 Howell Branch Road Facility. ... Chad Tomlinson , former Vice President of Operations, has ... Tomlinson is a Graduate of Florida State University and has ...
(Date:1/19/2017)... The global immunomodulators market is expected ... to a new study by Grand View Research, ... driven by high R&D investments employed by the ... new and therapeutically advanced drugs. This is believed ... unprecedented rate into the immunomodulators market hence providing ...
Breaking Medicine Technology: